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Regulatory Counteraction to IL-2 Activity 
M I C H A E L D KRAMER 1 and U L R I C H H. KOSZINOWSKP 
A rat ional approach to suppression of cellular immune responses requires detailed imformation on the mechanisms that regulate induction and differentiation of the ef-
fectOT cells involved. Recent research has led to a far more advanced knowledge of the 
T-cell activation process and in particular to the recognition of the central role of soluble 
mediators, in particular Interleukin-2 (IL-2). It appears that T-cell activation comprises a 
cascade of interdigitating mechanisms, some of which are antigen-specific and others of 
which are not. A theory has been elaborated by several authors that combines both 
antigen-specific and nonspecific events . ( 1 2 ) This theory implies that an antigen-specific 
initial Stimulus drives T-cells into an activated State, whereas further differentiation and 
clonal expansion of T-cells is regulated by antigen-nonspecific mediators, such as IL-2. 
The product ion of the latter is concomitantly initiated in the course of a cellular immune 
response. In Figure 1 we tried to depict the present concept for T-cell activation that is in-
spired by the results of several g roups . ( 1 6 ) 
It can be seen from this figure that the mediator IL-2, previously has been named T-cell 
Growth Factor (TCGF), ( 7 ) plays a central role in the generation of effector function by 
expanding activated cells. 
In view of the regulatory events accompanying an immune response this model requires 
antagonistic forces that either inactivate and /o r functionally restrain IL-2 activity. Conse-
quently several attempts have been made to investigate the mechanisms which accomplish 
this function. 
Most of the present Information has been obtained by applying strategies that are 
kflown to lead to suppression of immune responses, such as lectin-activated suppressor 
cells,(8"10) lectin- or antigen-induced suppressive factors, ( I 1 1 2 ) serum-derived suppressive 
activities,(13) or immunosuppressive d rugs . ( 1 4 I 7 ) 
The purpose of this article is to summarize briefly the results that have been obtained in 
tfeis particular field of research and finally to put forward an extended (still tentative) 
nnodel for T-cell activation (see Figure 2). No attempt is made to be exhaustive, especially 
wdth regard to including all references that had been relevant for the generation of the 
theory on T-cell activation outlined in Figure 1. Therefore review articles are cited and 
those may be consulted for the work that contributed to this theory. 
In recent publications by Northoff et al . , ( 9 ) Gullberg et al . , ( 8 ) and Palacios and 
Möller,(l0) it has been proposed that the production and function of IL-2 is regulated by 
suppressor cells. 
'Institute for Immunology and Genetics, German Cancer Research Center, D-6900 Heidelberg, 
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F I G . 1 . The role of IL-1 and IL-2 in T-cell activation. The activated macrophage releases IL-1 and 
presents antigen to the TH cell. The IL-2 released by the TH cell acts upon the IL-2 receptive CTL-precursor. The CTL-precursor acquires IL-2 responsiveness by antigen specific or mitogenic activa-
tion. Differentiation factors are required in parallel to IL-2 for maturation to effector function. 
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F I G . 2 . Schematic description of functional antagonists to IL-2 during T-cell activation. SF is pro-
duced by an activated suppressor cell and arrests the precursor cells of TH cells, Ts cells, and CTLs 
before they acquire sensitivity to IL-2. IL-2 that is not consumed is neutralized by the IL-2 inhibitor 
in the circulation. 
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Nonhoff et al.<9) described that fresh mononuclear leucocytes from human peripheral 
blood secreted very few or no IL-2 in the culture medium when stimulated with mitogen or 
antigen. Preincubation of these cells for 2-5 days in vitro rendered them capable of pro-
ducing and secreting increasing amounts of IL-2. Addition of increasing numbers of fresh 
leucocytes to such cultures gradually reduced IL-2 release. The suppressive effect was 
associated with the T-cell fraction and the authors concluded that shortlived suppressor 
T-cells prevent the production of IL-2 in fresh leucocyte cultures. 
Gullberg et al. ( 8 ) observed that IL-2 production in ConA stimulated murine spieen cell 
cultures shows a phasic time course with maximum production after 18 hr and a subse-
quent sharp decline, and postulated an active mechanism that limits IL-2 production. The 
decrease of IL-2 release (i) was not due to consumption of essential medium components, 
(ii) to inactivation of accessory cells, nor (iii) to activation of the lectin, (iv) was not caused 
by inhibitory substances that interfere directly with IL-2, and (v) cannot be explained by a 
feedback mechanism depending on previously produced IL-2. ConA activated spieen cells 
when transferred to a second culture exerted a dose dependent reduction of the de novo 
IL-2 production. Thus, they concluded that ConA induced suppressive cells account for 
the reduced IL-2 release from cells after 18-24 hr in vitro culture. 
Since ConA activated T-cells are the adequate responder- and consumer-celi population 
for IL-2 (19,20) the observed reduction of the IL-2 titer may in part be explained by absorp-
tion of IL-2 to its specific membrane receptors. (3 ,21) 
This was shown by Palacios and Möller<l0) who found that ConA activated human 
T-cells cause a marked suppression of P H A induced proliferation or of alloantigen induced 
cytolytic activity of leucocytes. The suppression was abrogated by addition of IL-2 to the 
detection system. Furthermore, when ConA activated suppressor cells were exposed to 
IL-2 prior to the addition to the detection system (i) they absorbed IL-2, and (ii) were 
functionally inactivated by IL-2. The authors therefore concluded that at least part of the 
suppressive activity of such cells is due to the reduction of the available IL-2. 
SUPPRESSIVE FACTOR(S) 
T-cell activation in vitro by lectins or antigen is followed by the generation of sup-
pressor cells(23) as well as by the release of suppressive mediators(23,24) into the cul-
ture medium. We isolated suppressive factor(s) from the supernatants of alloantigen 
stimulated murine spieen cells and tested their interference with T-cell activation. (1112) A 
factor(s) was separable from IL-2 by gel-filtration that inhibited the response of T-cells to 
alloantigen, as well as the generation of regulatory T-cells from their precursors when 
added at the beginning of the in vitro culture. Furthermore this factor(s) prevented the 
release of IL-2 from producer T-cells but had no detectable effect on the interaction of 
IL-2 with receptive T-cells. These experiments suggest that suppressive factor(s) do not 
directly interfere with IL-2 function but modulate early events in T-cell activation (see 
Figure 2) very likely by suppression of IL-2 release and by preventing T-cells to acquire 
IL-2 responsiveness. The main characteristics of this suppressive mediator(s) are sum-
marized in Table 1. 
We presently focus on the further biochemical purification and characterisation of the 
molecular species, which depends on large scale production of active supernatants under 
serum free conditions. Further studies with the at least semipurified factor are required to 
define the lineage and differentiation stage of its target cell, the mechanisms underlying 
the suppressive activity and its possible role in vivo. 
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TABLE 1. PROPERTIES OF S F 
Molecular weight 
Elution from DEAE-Sepharose 
Temperature stability 
pH stability 
10 000 d (as estimated from gel filtration) 
180 mM NaCl in 0.01 M Tris/HCl pH 8.0 
85% activity lost after 60 min at 70°C 
79% activity lost after 6 h at pH 4.0 
29% activity lost after 6 h at pH 10.0 
Induction 
Lymphoid target cell 
Inhibition of 3H-Thymidine uptake by T-cells 
Inhibition of CTL-induction (only when 
Antigen-specific, by T-cell mitogens 
T-cell 
Yes 
added early) 
Inhibition of IL-2 release 
Interference with IL-2 activity on T-cell 
Yes 
Yes 
blasts 
Producer cell No 
Not yet identified Data from references 11, 12, and 18. 
Suppressor factor(s) could be released independently from IL-2. If however the concen-
tration of IL-2 regulated the release of SF this should be considered in feasible thera-
peutical applications of IL-2. 
Hardt et al. (13) attempted to identify antagonists to the nonrestricted and nonspecific 
activity of IL-2 and found that normal mouse serum contains high levels of an IL-2 in-
hibitor with an apparent molecular weight of 55 000 daltons. A molecule(s) of this size in-
terfered directly with IL-2 and its mitogenic function on receptive T-cells. The inhibitory 
function was neither antigen-specific nor H-2 restricted. The actual titer of the inhibitory 
molecule seemed to be under the control of T-cells, since after cell transfer of allogeneic 
cyclophosphamide sensitive Lyt 2,3+ T-cells that induce a graft versus host reaction in 
nude mice, high serum levels of IL-2 inhibitor activity were found. 
Several authors have reported on the effects of immunosuppressive drugs on IL-2 release 
and function. Gillis et al . ( 1 6 1 7 ) analyzed whether glucocorticoids exert their suppressive ef-
fect on T-cell activation either at the level of the activated and IL-2 sensitive T-lymphocyte 
or at the level of IL-2 release. Mitogen induced IL-2 production and T-cell proliferation 
were completely inhibited by pharmacologic concentrations of dexamethasone, whereas 
the proliferation of splenocytes in the presence of maximum inhibitory doses of dex-
amethasone was restored by addition of IL-2. They concluded that a major pathway of 
glucocorticoid mediated immunosuppression leads to functional inhibition of the IL-2 
producing cell. 
Larsson (15) further studied the T-cell activation process using dexamethasone and in ad-
dition the microbial product Cyclosporin A, a cyclic octadecapeptide isolated from 
Cyclindrocarpum lucidum (CyA), which has selective immunosuppressive effects on 
T-lymphocytes.( 14,25,26 > CyA inhibited the acquisition of the lectin-induced responsiveness 
to IL-2 in resting T-cells at concentrations that did not affect the production of IL-2. CyA 
did not inhibit the IL-2 dependent division of T-cell blasts in response to IL-2, thus in-
SERUM-DERIVED INHIBITOR(S) OF IL-2 ACTIVITY 
INFLUENCE OF PHARMACOLOGICAL AGENTS ON 
IL-2 RELEASE AND FUNCTION 
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dicating that it did not interfere with the binding of IL-2 to its surface receptors nor with 
the subsequent response to the mitogenic signal. 
In contrast to CyA, dexamethasone at pharmacologic concentrations (10~5 to 10~7 M) (i) 
significantly reduced IL-2 production, (ii) but did not prevent T-lymphocytes to acquire 
responsiveness to IL-2, and (iii) left IL-2 mediated proliferation of T-cell blasts unaf-
fected. Furthermore, Larsson states that the reduced response of normal spieen cells to 
ConA in the presence of dexamethasone could be overcome to some extent by the addition 
of IL-1 isolated from the WEHI-3 macrophage cell line. This indicates that dex-
amethasone at nontoxic concentrations primarily interferes with the macrophage depen-
dent production of IL-1 , which then results in reduced IL-2 release. This is in accordance 
with earlier studies (27) showing that the macrophage metabolism is very sensitive to treat-
ment with glucocorticoids. 
SUMMARY AND CONCLUSIONS 
Summarizing the above mentioned findings it appears that T-cells after activation go 
through several stages of differentiation. Düring these stages they are susceptible to either 
activating or inhibitory factors, which restrict the response to regulatory mediators to a 
limited period. 
Taken together the data suggest that the release and function of IL-2 is regulated by 
several mechanisms (Figure 2): 
(i) IL-2 leaving the primary site of T-cell activation and entering systemic circulation 
may be inactivated by an IL-2 inhibitor present in the serum of normal mice. 
(ii) IL-2 liberated during T-cell activation can be absorbed by T-cells (T-suppressor cells) 
that are activated in parallel and that express the appropriate surface receptors. 
(iii) The de novo production of IL-2 is suppressed by suppressor cells and /or soluble 
mediators thereof. 
(iv) Generation of further IL-2 responsive T-cells is prevented by Inhibition of T-cells 
during the early phase of the activation process (either directly by suppressor T-cells 
and /o r via suppressive factors(s)). 
The principal mechanisms that could negatively regulate the effects of IL-2 are listed as 
follows: 
(i) Reduction of preformed IL-2 activity (ConA activated T-(suppressor-)cells, serum 
derived IL-2 inhibitor). 
(ii) Reduction of IL-2 production and release (ConA activated suppressor T-cells, alloan-
tigen induced suppressive factors(s), CyA at high concentrations, dexamethasone via 
reduction of IL-1). 
(iii) Inhibition of the acquisition of the IL-2 responsive State (CyA at lower concentra-
tions, alloantigen induced suppressive factor(s)). 
Recent results reported by several groups(28_31) indicate that the T-cell activation pro-
cess, and especially T-cell differentiation to active cytotoxic T-lymphocytes does in fact 
require further mediators in addition to IL-1 and IL-2. This was concluded from studies 
showing that IL-2 alone (derived from a T-cell hybridoma cell line) causes proliferation 
but is not sufficient to give rise to active CTL in accessory cell depleted T-cell cultures. 
However, a mixture of IL-2 and IL-2 depleted conditioned medium from spieen cells 
resulted in füll differentiation to active CTL. ( 2 8 ) Further studies will have to clear the role 
of physiological and pharmacological immunosuppressants in the network of factors Con-
trolling T-cell proliferation and differentiation. 
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